Cancer centre chooses PDS Life Sciences' software for preclinical research

The Memorial Sloan Kettering Cancer Center has opted to use PDS Life Sciences' Ascentos software suite to manage and analyse data that will be generated in its new GLP-compliant preclinical research laboratories.

Ascentos software includes toxicology, clinical pathology, reproductive toxicology and pathology modules that interface seamlessly to streamline data management from study setup to final reporting. Ascentos is a complete FDA SEND-ready preclinical solution because it captures data required by current and future versions of the CDISC SEND data standard.

“We’re honoured to have Memorial Sloan Kettering as a client,” said Sayed Badrawi, CEO of PDS. “The institute is world-renowned for contributing to the discovery and development of oncology therapies, and its choice validates Ascentos as the new gold standard for ease of use, flexibility and rapid implementation.”

PDS guarantees system validation in reasonable time periods and simplifies setup and usage training. After a rigorous, competitive assessment, the cancer center selected Ascentos because of its intuitive processes, rapid implementation and ability to automate fundamental laboratory workflows.

“We develop software that works like scientists think,” said Badrawi. “As innovative companies and research institutions continue to choose PDS’ Ascentos over the alternatives, it’s become clear that building software for the user — not just the data being compiled — is a key driver of value in the market.”